RepliCel Life Sciences Inc
0913693 B.C. Ltd., a regenerative medicine company, develops autologous cell therapies for the treatment of functional cellular deficits. Its treatments use autologous cell therapy to treat chronic tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company's product candidates include … Read more
RepliCel Life Sciences Inc (REPCF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.021x
Based on the latest financial reports, RepliCel Life Sciences Inc (REPCF) has a cash flow conversion efficiency ratio of 0.021x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-25.09K) by net assets ($-1.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
RepliCel Life Sciences Inc - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how RepliCel Life Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
RepliCel Life Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of RepliCel Life Sciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MagForce AG
PINK:MGFRF
|
N/A |
|
Enzychem Lifesciences Corporation
KO:183490
|
-0.013x |
|
NWS HLDGS
BE:NWS
|
N/A |
|
Energent AG
MU:EM6
|
N/A |
|
CPU Softwarehouse AG
F:CPU2
|
-0.015x |
|
112190
KO:112190
|
N/A |
|
TRANSGENE (TGNA.SG)
STU:TGNA
|
N/A |
|
El Nasr For Manufacturing Agricultural Crops
EGX:ELNA
|
N/A |
Annual Cash Flow Conversion Efficiency for RepliCel Life Sciences Inc (2003–2024)
The table below shows the annual cash flow conversion efficiency of RepliCel Life Sciences Inc from 2003 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-4.51 Million | $-530.86K | 0.118x | -62.29% |
| 2023-12-31 | $-4.53 Million | $-1.41 Million | 0.312x | +30.98% |
| 2022-12-31 | $-5.92 Million | $-1.41 Million | 0.238x | -35.15% |
| 2021-12-31 | $-6.84 Million | $-2.51 Million | 0.367x | +143.00% |
| 2020-12-31 | $-5.06 Million | $-765.21K | 0.151x | -75.95% |
| 2019-12-31 | $-4.43 Million | $-2.78 Million | 0.629x | -25.90% |
| 2018-12-31 | $-455.18K | $-386.10K | 0.848x | -94.96% |
| 2017-12-31 | $-320.00K | $-5.39 Million | 16.831x | +672.92% |
| 2016-12-31 | $1.21 Million | $-3.54 Million | -2.938x | -140.53% |
| 2015-12-31 | $-601.78K | $-4.36 Million | 7.248x | +394.45% |
| 2014-12-31 | $1.81 Million | $-4.45 Million | -2.461x | -833.89% |
| 2013-12-31 | $1.47 Million | $494.59K | 0.335x | +100.24% |
| 2012-12-31 | $21.16K | $-2.96 Million | -139.792x | -1701.22% |
| 2011-12-31 | $401.45K | $-3.12 Million | -7.761x | -532.64% |
| 2010-12-31 | $685.45K | $-840.87K | -1.227x | -237.75% |
| 2009-12-31 | $-190.83K | $-169.94K | 0.891x | +73.31% |
| 2008-12-31 | $-270.48K | $-138.99K | 0.514x | -76.06% |
| 2007-12-31 | $-99.48K | $-213.50K | 2.146x | +200.08% |
| 2006-12-31 | $171.30K | $-367.33K | -2.144x | +42.80% |
| 2005-12-31 | $25.23K | $-94.58K | -3.749x | -724.37% |
| 2004-12-31 | $-89.61K | $-53.80K | 0.600x | 0.00% |
| 2003-12-31 | $-89.61K | $-53.80K | 0.600x | -- |